share_log

Demant A/S (OTCMKTS:WILYY) Vs. Bone Biologics (OTC:BBLG) Financial Analysis

Demant A/S (OTCMKTS:WILYY) Vs. Bone Biologics (OTC:BBLG) Financial Analysis

Demant A/S (OTCMKTS: WILYY) vs.Bone Biologics（场外交易代码：BBLG）财务分析
Defense World ·  2023/01/13 03:21

Demant A/S (OTCMKTS:WILYY – Get Rating) and Bone Biologics (OTC:BBLG – Get Rating) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Demant A/S（OTCMKTS: WILYY — 获取评级）和 Bone Biologics（OTC: BBLG — 获取评级）都是医疗公司，但哪一项是最佳投资？我们将根据两家企业的盈利能力、机构所有权、估值、收益、股息、风险和分析师建议对比这两家企业。

Volatility and Risk

波动性和风险

Demant A/S has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, Bone Biologics has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500.

Demant A/S的beta值为0.52，这表明其股价的波动性比标准普尔500指数低48％。相比之下，Bone Biologics的beta值为0.24，这表明其股价的波动性比标准普尔500指数低76％。

Get
获取
Demant A/S
Demant A/S
alerts:
警报：

Analyst Recommendations

分析师建议

This is a breakdown of recent ratings and recommmendations for Demant A/S and Bone Biologics, as reported by MarketBeat.com.

这是Marketbeat.com报道的Demant A/S和Bone Biologics最近的评级和推荐明细。

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Demant A/S 4 0 1 0 1.40
Bone Biologics 0 0 1 0 3.00
卖出评级 保持收视率 买入评级 强劲的买入评级 评分分数
Demant A/S 4 0 1 0 1.40
骨生物制剂 0 0 1 0 3.00
Bone Biologics has a consensus price target of $2.25, suggesting a potential upside of 650.00%. Given Bone Biologics' stronger consensus rating and higher possible upside, analysts plainly believe Bone Biologics is more favorable than Demant A/S.
Bone Biologics的共识目标股价为2.25美元，表明潜在的上涨空间为650.00％。鉴于Bone Biologics更强的共识评级和更高的可能上行空间，分析师显然认为Bone Biologics比Demant A/S更有利。

Insider & Institutional Ownership

内部所有权和机构所有权

7.6% of Bone Biologics shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

7.6％的Bone Biologics股份由机构投资者持有。强大的机构所有权表明对冲基金、大型基金经理和捐赠机构认为股票有望实现长期增长。

Profitability

盈利能力

This table compares Demant A/S and Bone Biologics' net margins, return on equity and return on assets.

该表比较了Demant A/S和Bone Biologics的净利润率、股本回报率和资产回报率。

Net Margins Return on Equity Return on Assets
Demant A/S N/A N/A N/A
Bone Biologics N/A 7,587.33% 7,258.20%
净利润 股本回报率 资产回报率
Demant A/S 不适用 不适用 不适用
骨生物制剂 不适用 7,587.33% 7,258.20%

Earnings and Valuation

收益和估值

This table compares Demant A/S and Bone Biologics' gross revenue, earnings per share and valuation.

该表比较了Demant A/S和Bone Biologics的总收入、每股收益和估值。

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Demant A/S $2.93 billion 2.26 $399.82 million N/A N/A
Bone Biologics N/A N/A -$1.61 million N/A N/A
总收入 价格/销售比率 净收入 每股收益 市盈率
Demant A/S 29.3 亿美元 2.26 3.9982 亿美元 不适用 不适用
骨生物制剂 不适用 不适用 -161 万美元 不适用 不适用

Demant A/S has higher revenue and earnings than Bone Biologics.

Demant A/S的收入和收益高于Bone Biologics。

Summary

摘要

Bone Biologics beats Demant A/S on 5 of the 8 factors compared between the two stocks.

在这两只股票比较的8个因素中，Bone Biologics在5个因素上击败了Demant A/S。

About Demant A/S

关于 Demant A/S

(Get Rating)

（获取评分）

Demant A/S, a hearing healthcare and audio technology company, develops, manufactures, and sells products and equipment to enhance people's hearing in Europe, North America, the Pacific, Asia, and internationally. It operates in two segments, Hearing Healthcare and Communications. The Hearing Healthcare segment offers hearing implants and aids, hearing care, and diagnostic products. The Communications segment provides headsets for collaborative work and gaming markets under the EPOS brand name. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark.

Demant A/S 是一家听力保健和音频技术公司，开发、制造和销售产品和设备，以增强欧洲、北美、太平洋、亚洲和国际上人们的听力。它分为两个部门：听力保健和通讯。听力保健部门提供听力植入物和助听器、听力保健和诊断产品。通信部门以EPOS品牌为协作工作和游戏市场提供耳机。该公司前身为 William Demant Holding A/S，并于 2019 年 3 月更名为 Demant A/S。Demant A/S 成立于 1904 年，总部位于丹麦斯莫鲁姆。

About Bone Biologics

关于 Bone Biologics

(Get Rating)

（获取评分）

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.

Bone Biologics Corporation是一家医疗器械公司，专注于使用重组人蛋白在脊柱融合中的骨再生。该公司的NELL-1/DBX是一种组合产品，它是一种骨刺激性重组蛋白，可为骨再生提供靶向特异性控制。它正在开发 NELL-1/DBX 融合设备，用于治疗骨骼成熟的椎间盘退行性疾病患者，其水平与 L4-S1 相同。该公司的平台技术已应用于在脊柱、骨科、普通骨科、整形重建、神经外科、介入放射学和运动医学等外科专业领域提供增强的疗效。它与加州大学洛杉矶分校技术开发小组签订了许可协议，用于脊柱融合应用的 NELL-1 的开发和商业化。该公司成立于 2004 年，总部位于马萨诸塞州伯灵顿。

Receive News & Ratings for Demant A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Demant A/S and related companies with MarketBeat.com's FREE daily email newsletter.

每天接收 Demant A/S 的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Demant A/S及相关公司的最新新闻和分析师评级的简明每日摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发